Changing management in patients with papillary thyroid cancer

Keyphrases

• Change Management 100%
• Papillary Thyroid Cancer 100%
• Radioactive Iodine 66%
• Resection 50%
• Metastatic Disease 33%
• Thyroglobulin 33%
• Thyroid Cancer 33%
• Thyroglobulin Level 33%
• Cervical Lymph Node 33%
• Neck Ultrasound 33%
• Chemotherapy 16%
• Major Change 16%
• Tumor 16%
• Distant Metastasis 16%
• Surgical Treatment 16%
• Patient Management 16%
• Antiangiogenic Agents 16%
• Common Cancers 16%
• Treatment Dose 16%
• Primary Tumor 16%
• Complication Rate 16%
• Whole-body 16%
• Thyroxine 16%
• Locoregional 16%
• Regional Lymph Nodes 16%
• Clinical Follow-up 16%
• Tyrosine Kinase Inhibitor 16%
• Initial Treatment 16%
• Lobectomy 16%
• Thyroid Gland 16%
• Consensus Guidelines 16%
• Postoperative Adjuvant Chemotherapy 16%
• Lymph Node Disease 16%
• Lymph Node Dissection 16%
• Postoperative Follow-up 16%
• Non-culprit Lesion 16%
• Thyroid Lobectomy 16%
• Near Total Thyroidectomy 16%
• Emerging Therapies 16%
• Redifferentiation 16%
• Thyroid-stimulating Hormone Suppression 16%
• Endocrine Surgeons 16%
• Spread Pattern 16%
• Iodine Scan 16%
• Cervical Lymph Node Metastasis 16%
• Radioactive Iodine Ablation 16%
• Multicentric Disease 16%

Medicine and Dentistry

• Papillary Thyroid Cancer 100%
• Radioactive Iodine 83%
• Surgery 66%
• Metastatic Carcinoma 33%
• Thyroid Cancer 33%
• Neck 33%
• Cervical Lymph Node 33%
• Thyroglobulin 33%
• Diseases 16%
• Neoplasm 16%
• Adjuvant Therapy 16%
• Chemotherapy 16%
• Primary Tumor 16%
• Lymph Node 16%
• Thyroidectomy 16%
• Retroperitoneal Lymph Node Dissection 16%
• Malignant Neoplasm 16%
• Distant Metastasis 16%
• Lymphadenopathy 16%
• Angiogenesis Inhibitor 16%
• Tyrosine-Kinase Inhibitor 16%
• Lobectomy 16%
• Thyrotropin 16%
• Thyroxine 16%
• Subtotal Thyroidectomy 16%
• Cervical Lymph Node Metastasis 16%
• Surgeon 16%